Summary:
You are invited to
take part in this study because you have cardiovascular disease, high blood
pressure and type 2 diabetes. We are doing this study to
learn more about treatments that could
reduce the risk of developing heart failure, reduce the risk of death from
cardiovascular causes and also to better
understand the studied disease and associated health problems. This study will
investigate the benefits and safety of study treatment with an investigational
drug called baxdrostat in combination with dapagliflozin in participants at an
increased risk of developing heart failure.
Qualified Participants Must:
• Be ≥ 40 years old at the time of signing the informed consent
•
Diagnosed with T2DM and requiring treatment
•
Must have Established CV disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease)
•
Must have History of HTN
•
Must have least one additional risk factor for HF:
- Age ≥ 70 years
- UACR >20 mg/g
- eGFR <60 mL/min/1.73 m2
- History of polyvascular disease (at least two of: ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease) (see Appendix F 1)
- History of atrial fibrillation or atrial flutter
- NT-proBNP >125 ng/L
Qualified Participants May Receive:
Up to $1,900 on completion of study